Immunicum AB (publ) Announces Participation at Conferences in June
(Thomson Reuters ONE) -
Press Release
30 May 2017
Immunicum AB (publ) Announces Participation at Conferences in June
Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company
advancing a novel immuno-oncology treatment against a range of solid tumors,
today announced that Carlos de Sousa, MD, CEO of Immunicum, has been invited to
present the Company at several upcoming conferences in June and to participate
on a panel titled "New Frontiers in Oncology". In addition, the Company will
attend the 2017 BIO International Convention.
Sachs Associates 3rd Annual Immuno-Oncology BD&L and Investment Forum
Date: June 2, 2017
Presentation Time: 11:10 am Central Standard Time
Venue: Hyatt Centric Chicago Magnificent Mile Hotel, Chicago, Illinois
Labiotech Refresh
Date: June 8, 2017
Panel: "New Frontiers in Oncology" 10:30 am Central European Time
Venue: Spreewerkstätten, Berlin, Germany
Småbolagsdagen
Date: June 12, 2017
Presentation Time: 9:20 - 9:50 am Central European Time
Venue: Sheraton Hotel Stockholm, Stockholm, Sweden
For those who can't participate, the presentation from Småbolagsdagen will be
available afterwards on Immunicum's website and will also be broadcasted live on
www.smabolagsdagen.net
2017 BIO International Convention (attendance only)
Date: June 19-22, 2017
Venue: San Diego Convention Center, San Diego, California
For more information, please contact:
Carlos de Sousa, VD, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info(at)immunicum.com
Investor Relations Sweden
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: helena.stangberg(at)halvarsson.se
Investor and Media Relations EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or +49 175 5711562
E-mail: gschweitzer(at)macbiocom.com or smay(at)macbiocom.com
The Company's Certified Adviser is Redeye AB
Telephone: +46 (0) 8 545 013 31
www.redeye.se
About Immunicum AB (publ)
Immunicum AB (First North Premier: IMMU.ST) is a clinical stage Company
developing novel immuno-oncology therapies against a range of solid tumors.
The Company's lead compound, INTUVAX® is currently being evaluated in clinical
trials for the treatment of kidney cancer, liver cancer and gastrointestinal
stromal tumors. INTUVAX® was designed to combine the best of two worlds: a
cost-effective cell-based (allogeneic) and off-the-shelf therapy that is
capable of triggering a highly personalized and potentially long-lasting
immune response against tumor cells throughout the body. www.immunicum.com
-------------------------------------------------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Caledonia Mining Corporation Plc: Purchase of Shares by a DirectorDatum: 30.05.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 545071
Anzahl Zeichen: 3577
contact information:
Town:
Gothenburg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 158 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Immunicum AB (publ) Announces Participation at Conferences in June"
steht unter der journalistisch-redaktionellen Verantwortung von
Immunicum AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
